Bull flag with high volume on 4H30D chart, w/ potential catalyst
~130mm market cap biotech firm, with multiple products in the pipeline based on their patented Versamune nanoparticle platform.
Recently spiked on announcement of award of 60mm from Brazilian Ministry of Science & Technology to fund phase 1/2 clinical trials for a potential Covid vaccine based on their Verasmune platform.
Since the news, avg vol (10day) is now 6.5million compared to avg vol (3 month) of 1.7 million. Float of the company is 17.17 million, with approximately 30million cash on hand and a burn rate of ~5mill per quarter. Hopefully, no immediate offerings.
Since initial spike, chart has held steady between $5.50 and $5.00 resistance/support, with it never closing below 5 on the 4 hour candles. On the 24th of March, "Dr. Frank Bedu-Addo, CEO of PDS Biotech, will present the company’s immunotherapy platform, ongoing phase 2 clinical programs, product pipeline and upcoming milestones virtually at the Benzinga Biotech Small Cap Conference"
If any interesting information is announced during this conference, it will be interesting to see how the price action follows. Long on this thesis.
Recently spiked on announcement of award of 60mm from Brazilian Ministry of Science & Technology to fund phase 1/2 clinical trials for a potential Covid vaccine based on their Verasmune platform.
Since the news, avg vol (10day) is now 6.5million compared to avg vol (3 month) of 1.7 million. Float of the company is 17.17 million, with approximately 30million cash on hand and a burn rate of ~5mill per quarter. Hopefully, no immediate offerings.
Since initial spike, chart has held steady between $5.50 and $5.00 resistance/support, with it never closing below 5 on the 4 hour candles. On the 24th of March, "Dr. Frank Bedu-Addo, CEO of PDS Biotech, will present the company’s immunotherapy platform, ongoing phase 2 clinical programs, product pipeline and upcoming milestones virtually at the Benzinga Biotech Small Cap Conference"
If any interesting information is announced during this conference, it will be interesting to see how the price action follows. Long on this thesis.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.